LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

LLY

966.35

+1.98%↑

JNJ

221.39

+0.12%↑

ABBV

202.82

+0.84%↑

UNH

384.32

+1.29%↑

AZN

181.82

-0.27%↓

Home・Aandelen Lijst・Ovid therapeutics Inc

Ovid therapeutics Inc

Gesloten

SectorGezondheidszorg

2.79

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

2.74

Max

2.9

Belangrijke statistieken
By Trading Economics
Inkomsten	22M 9.7M
Verkoop	586K 718K
Winstmarge	1,345.822
Werknemers	23
EBITDA	-152K -12M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+79.64% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	368M 507M
Vorige openingsprijs	2.79
Vorige sluitingsprijs	2.79

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

0.275 / 0.33 Steun & Weerstand

Ovid therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

11 mei 2026, 22:15 UTC

Acquisities, Fusies, Overnames

BMO Financial Group to Sell Transportation-, Vendor-Finance Businesses to Stonepeak

11 mei 2026, 23:46 UTC

Marktinformatie

Yen Consolidates as Traders Await Bessent's Meetings -- Market Talk

11 mei 2026, 23:44 UTC

Marktinformatie

Nikkei May Rise on AI Enthusiasm -- Market Talk

11 mei 2026, 23:33 UTC

Marktinformatie

Gold Rises on Possible Position Adjustments -- Market Talk

11 mei 2026, 22:37 UTC

Marktinformatie

CSL's Profit, Revenue Downgrade 'Not a Complete Surprise' -- Market Talk

11 mei 2026, 22:32 UTC

Winsten

Verde Clean Fuels 1Q Loss/Shr 5c >VGAS

11 mei 2026, 22:02 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Stellar Auto Sales Increase in Canada Could Be Tied to Return of EV Incentives -- Market Talk

11 mei 2026, 21:49 UTC

Winsten

Rigetti Computing Revenue Triples. Why the Quantum Stock Is Falling. -- Barrons.com

11 mei 2026, 21:42 UTC

Marktinformatie

Declining Hours Worked Should Keep Bank of Canada Firmly on Hold -- Market Talk

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

Bank of Montreal to Sell Transportation Finance and Vendor Finance Businesses to Stonepeak

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Supports Strategy to Elevate Returns and Accelerate Growth, Transaction Accretive to Cap Ratios and ROE >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: Positions Businesses for Continued Growth in Efficient Cap Structure >BMO.T

11 mei 2026, 21:32 UTC

Acquisities, Fusies, Overnames

BMO: To Invest in 19.9% Equity Interest, Enabling Continued Participation in the Businesses' Long-Term Value Creation >BMO.T

11 mei 2026, 21:31 UTC

Acquisities, Fusies, Overnames

BMO: Announces Strategic Sale of Transportation and Vendor Finance Businesses

11 mei 2026, 21:23 UTC

Acquisities, Fusies, Overnames

CSG Systems Sale to NEC Gets CFIUS Clearance

11 mei 2026, 21:12 UTC

Winsten

Ovintiv: Full-Yr Production Volumes Expected to Avg 620 to 645 MBOE/d, Full-Yr Expected Cap Investment of $2.25B to $2.35B >OVV

11 mei 2026, 21:12 UTC

Winsten

Ovintiv 1Q Loss/Shr $2.35 >OVV

11 mei 2026, 20:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

11 mei 2026, 20:44 UTC

Winsten

Steris: Board Approves New $1B Shr Repurchase Program >STE

11 mei 2026, 20:43 UTC

Winsten

Whirlpool Shares Are Still Falling. Last Week's Earnings Might Be Why. -- Barrons.com

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Loss/Shr $1.52 >CLSK

11 mei 2026, 20:32 UTC

Winsten

CleanSpark 2Q Rev $136.4M >CLSK

11 mei 2026, 20:30 UTC

Winsten

Hims & Hers Stock Sinks. Why Earnings Offered Wall Street a Big Surprise. -- Barrons.com

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Cont Ops EPS $2.24 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Rev $1.6B >STE

11 mei 2026, 20:30 UTC

Winsten

Steris Sees FY Adj EPS $11.10-Adj EPS $11.30 >STE

11 mei 2026, 20:30 UTC

Winsten

Steris 4Q Adj EPS $2.83 >STE

11 mei 2026, 20:22 UTC

Populaire aandelen

Stocks to Watch: Moderna, Intel, Micron, Fox -- WSJ

11 mei 2026, 19:37 UTC

Winsten

More Bad News at KKR's Private Credit Fund -- Barrons.com

11 mei 2026, 19:32 UTC

Marktinformatie

Oil Gains As Trump Rejects Iran's Response to U.S. Plan -- Market Talk

Peer Vergelijking

Prijswijziging

Ovid therapeutics Inc Prognose

Koersdoel

By TipRanks

79.64% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 5.03 USD 79.64%

Hoogste 7 USD

Laagste 4 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ovid therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ovid therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

0.275 / 0.33Steun & Weerstand

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.